US FDA Approves Exdensur (depemokimab) for Severe Asthma Treatment
GSK's Exdensur (depemokimab) has been approved by the US FDA as a twice-yearly treatment for severe eosinophilic asthma in patients aged 12 and older, based on phase III trial data showing significant reduction in exacerbations and hospitalizations, with a favorable safety profile.